
D-Valneb 250 Tablet ER
Marketer
Kachhela Medex Pvt Ltd
Salt Composition
Divalproex (250mg)
Overview D-Valneb 250 Tablet ER
Valneba XR 250mg extended-release tablets are prescribed for epilepsy management, preventing and controlling seizures. They're also indicated for migraine prophylaxis and, in some cases, bipolar disorder treatment. Valneba XR 250mg may be administered alone or concurrently with other medications; dosage and frequency are determined by your physician to optimize symptom control. This medication can be taken with or without food, but consistent daily timing is crucial for efficacy. Therapeutic effects generally manifest within a few weeks. Continuous use, as directed, is essential; missed doses risk seizure recurrence, and abrupt cessation can worsen your condition. Discontinuation should always be gradual. Common side effects include headache, blurred vision, nausea, vomiting, dizziness, fatigue, imbalance, easy bruising, and hypothermia. While most are mild, persistent or bothersome effects warrant medical consultation. Report any skin rash or redness immediately. Prolonged use may cause osteoporosis, increasing fracture risk, and rarely, suicidal ideation or behavior. Report any depressive symptoms to your doctor. Prior to commencing treatment, inform your physician of any history of heart disease, renal or hepatic impairment, urinary difficulties, depression, or suicidal tendencies. Drug interactions are possible; disclose all current medications to ensure safety. Consult your physician before initiating or discontinuing Valneba XR 250mg during pregnancy. Alcohol consumption should be avoided due to potential side effect exacerbation and increased seizure risk. Regular blood monitoring, both pre- and post-treatment initiation, may be necessary for optimal dosage adjustment.
Uses of D-Valneb 250 Tablet ER
Managing epileptic seizures and bipolar disorder; migraine prevention.
Major Benefits of D-Valneb 250 Tablet ER:
Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. D-Valneb 250 Extended-Release Tablets may be consumed with or without food, however, consistent daily timing is recommended.
Common Side effects of D-Valneb 250 Tablet ER:
- Decreased body temperature
- Dizziness
- Sleepiness
- Tremors
- Paresthesia (tingling or pricking sensation)
- Anemia (low number of red blood cells)
- Decreased sodium level in blood
- Liver injury
- Gastrointestinal disturbance
- Hypersensitivity
- Deafness
- Urinary incontinence
- Increase in body weight
- Pain during periods
How to use D-Valneb 250 Tablet ER:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. D-Valneb 250 Extended-Release Tablets can be consumed with or without food, though consistent timing is recommended.
How D-Valneb 250 Tablet ER works:
Extended-release D-Valneb 250 mg tablets are used to manage epilepsy. Their mechanism of action involves reducing hyperactive neuronal firing in the brain, thus controlling seizures.
SAFETY ADVICE
AlcoholUNSAFE
Taking D-Valneb 250 Extended-Release tablets with alcohol can lead to significant sleepiness.
PregnancyCONSULT YOUR DOCTOR
Extended-release D-Valneb 250mg tablets pose a confirmed risk to fetal development and should not be taken during pregnancy. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingSAFE IF PRESCRIBED
Extended-release D-Valneb 250mg tablets are considered safe for use while breastfeeding. Research in humans indicates minimal drug transfer into breast milk, posing no known risk to the infant.
DrivingUNSAFE
Extended-release D-Valneb 250mg tablets can induce adverse reactions that might impair driving capabilities.
KidneySAFE IF PRESCRIBED
Extended-release D-Valneb 250 mg tablets are considered safe for use in individuals with kidney impairment. No alteration of the D-Valneb 250 mg extended-release tablet dosage is necessary.
LiverUNSAFE
Extended-release D-Valneb 250 mg tablets are likely contraindicated for individuals with hepatic impairment and should be omitted. Physician consultation is advised.
What if you forget to take D-Valneb 250 Tablet ER :
Should you forget a dose of D-Valneb 250 Tablet ER, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About D-Valneb 250 Tablet ER
| Label | Value |
|---|---|
| Chemical Classification | Derivatives of Aliphatic Carboxylic Acids |
| Developing Habits | No. |
| Treatment Category | Neuroscience and Central Nervous System |
| Behavioral Class | Antiepileptic drugs targeting sodium channels |
